Cart
sales@molnova.com
Linzagolix
CAS No. 935283-04-8
Linzagolix( —— )
Catalog No. M27897 CAS No. 935283-04-8
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 89 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 269 | In Stock |
|
| 50MG | 431 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLinzagolix
-
NoteResearch use only, not for human use.
-
Brief DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
-
DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number935283-04-8
-
Formula Weight508.42
-
Molecular FormulaC22H15F3N2O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (245.86 mM)
-
SMILESCOc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Trujillo C, Goya P, Rozas I. Study of Meldrum's Acid Cyclization Reactions. J Phys Chem A. 2018 Mar 8;122(9):2535-2541.
molnova catalog
related products
-
Bexmarilimab
Bexmarilimab (FP-1305) is a highly potent, humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM, promoting immune conversion of tumor-associated macrophage phenotype M2 to M1, and can be used to study cancer.
-
SY-5609
CDK7-IN-3 is a selective CDK7 inhibitor with a KD of 0.059 nM. CDK7-IN-3 shows poor inhibition on CDK2 (Ki=390 nM), CDK9 (Ki=290 nM), CDK12 (Ki=78 nM). CDK7-IN-3 induce apoptosis in tumor cells and has antitumor activity.
-
Cinaciguat
Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.
